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HUMAN monocytes, preincubated with IFN-%
respond to IL-4 by a cGMP increase through acti-
vation of an inducible NO synthase. Here, IL-4
was found to induce an accumulation of cGMP
(1- rain) and cAMP (20- 25 min) in unstimu-
lated monocytes. This was impaired with NOS
inhibitors, but also with EGTA and calcium/cal-
modulin inhibitors. These results suggest that: (1)
IL-4 may stimulate different NOS isoforms in
resting and IFN-T activated monocytes, and (2)
c_AMP accumulation may be partially dependent
on the NO pathway. By RT-PCR, a type III con-
stitutive NOS mRNA was detected in U937 mono-
cytic cells. IL-4 also increased the [Ca2]l in these
cells. Different NOS may thus be expressed in
monocytic cells depending on their differentia-
tion and the signals they receive.
Key words: [Ca
2+ ]i, cAMP, cGMP, Human monocytes, IL-
4, NO synthase.
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Introduction
Interleukin-4 (IL-4) is a 20kDa glycoprotein,
produced by activated T lymphocytes (Th2), mast
cells, basophils and other cell types, which dis-
plays a broad spectrum of biological activity on
haematopoietic cells. On monocytes/macro-
phages, IL-4 enhances the expression of MHC
class II antigens, adhesion molecules of the LFA-1
(leucocyte functional antigen) family
2 and CD23.
In contrast, IL-4 down-regulates the expression of
Fc3,RI (CD64) and Fc3,RII (CD32) and inhibits
the induction of Fc3tRIII (CD16) by IFN-3t
4 or
TGF-[3.
5 IL-4 also down-regulates the expression
of CD14 on monocytes.
6 IL-4 acts as an anti-
inflammatory mediator by decreasing the release
of IL-1, TNF-a, IL-6, IL-8 and prostaglandin E2 by
human monocytes and by reducing their capacity
to produce reactive oxygen species.
7-12 IL-4 also
induces the secretion of G- and M-CSF by mono-
cytes3 and triggers their differentiation into mac-
rophage-like cells type in vitro.
The binding component of the IL-4 receptor
belongs to the family of haemapoietin recep-
tors14a5 and is associated, at least in some cell
types, to the y chain previously reported for the
16 22 IL-2 receptor. The importance of protein tyr-
osine phospholation in IL-4 signalling is now
23 28 29 well recognized and recently, the Jak-3 and
0 Lsk3 have been identified as the major tyrosine
kinases involved. Several transcription factors are
selectively activated through IL-4-induced tyrosine
phosphorylation.3’2
We recently described that IL-4 induced an
accumulation of cGMP in monocytes of certain
donors, which was greatly enhanced by pre-
incubation with IFN-3t and was dependent on the
t-arginine-dependent pathway of nitric oxide syn-
thase (NOS) activation, since it was markedly
reduced in the presence of NOS inhibitors.33 We
also reported that IL-4 displayed a biphasic effect
on the capacity of cultured monocytes to release
nitrite in their supernatants.4 in the present
work, we have further analysed the effect of It-4
on the production by monocytic cells of the
cyclic nucleotides cAMP and cGMP.
Materials and Methods
Reagents: Recombinant human IL-4 obtained
from Escherichia coli (specific activity, 1 x 107U/
mg, 1 U 1 ng) was purchased from Immugenex
(Los Angeles, CA, USA). Isobutyl methyl xanthine
(IBMX), EGTA (ethylene glycol-bis([3-aminoethy-
lether) N,N,N’,N’-tetraacetic acid) and the two
inhibitors of calmodulin, calmidazolium and W-7,
were purchased from Sigma (Saint Louis, MO,
USA). A-mono-methyl-t-arginine (t-NMMA) and
A-nitro-I.-arginine (t-NA), two N-guanido-sub-
stituted analogues of t-arginine, competitive inhi-
bitors of NO synthase, were purchased from
Calbiochem and Sigma, respectively. The neu-
tralizing anti-IL-4 mAb was from Immunotech
(Luminy, France).
Isolation of human monocytes: Blood samples
were obtained from cytapheresis of normal
donors, as residues of platelet preparations,
thorugh the courtesy of the blood transfusion
centres of Cr6teil and H6tel-Dieu. Blood donors
298 Mediators of Inflammation Vol 4. 1995 (C) 1995 Rapid Science PublishersIL-4 triggers cAMP and cGMP in monocytes
did not show contamination by HIV and hepatitis for 15 min at 4C. The neutralized supernatants
B, or suffer from manifestations of allergy. Other- were kept frozen at -70C until cGMP and
wise their clinical and immunological status was cAMP determinations. After acetylation of the
not known. Peripheral blood mononuclear cells samples, the concentrations of cGMP and cAMP
(PBMC) were purified as previously described.2 were determined by specific radioimmunoassays,
Briefly, blood samples were centrifuged at according to the specifications of the manu-
200 x g for 10 min in order to eliminate the factumrs (kits from Amersham France, Les Ulis
residual contaminating platelets. Then, samples or from NEN, Dupont, Dreieich, Germany). The
were diluted in RPMI 1640 medium (Bioproduct, significance of the results was analysed by the
tes Ulis, France) and PBMC were harvested after Student’s t-test, adapted for small samples.
a 20 min centrifugation at 800 x g on Ficoll-
Hypaque (Pharmacia, Uppsala, Sweden)gradient. Identification of constitutive NO synthase in
Adherent cell populations were obtained by incu- monocytic cells by reverse transcription-poly-
bation of PBMC (1 x 10v cells/ml) in Petri merase chain reaction: Total RNA samples were
dishes (Nunc, Rocksille, Denmark) for I h at extracted from monocytes and U937 cells by a
37C in RPMI 1640 medium supplemented with modification of the technique of MacDonald et
10% FCS (Gibco, Paisley, UK). Monocytes were a/.5 Briefly, cells were washed twice in ice-cold
harvested by scraping the plates with a rubber PBS then resuspended in 1.5 ml of 5M guanidi-
policeman after addition of cold phosphate-buf- nium thiocyanate (Fluka, Buchs, Switzerland).
femd saline solution (PBS) containing ImM After sonication for 20s in a Vibra Cell sonifier
EDTA. Cell preparations were composed of more (Bioblock Scientific, Illkirch, France) at 40%
than 95% viable monocytes as assessed by the maximal power, the cell lysates were layered on
Tpan blue exclusion method and nonspecific 1.5 ml cushions of 5.7M CsCl dispensed in poly-
esterase staining. Other contaminating cells were carbonate tubes and centrifuged at 20 000 x g
lymphocytes and granulocytes which never for 3 h at 20C in the TLA 100.3 rotor of a TL
exceeded 5% of the total cell number, whereas 100 ultracentrifuge (Beckman Instruments). After
platelet contamination was undetectable, two washings with formamide/ethanol (30/70
v/v), the pellet was dried and resuspended in
Monocytic cell line: U937 promonocytic cells 2001.tl of TE buffer (Tris 10mM, EDTA l mM).
were maintained in RPMI-1640 medium (Gibco, After addition of 0.1 vol of 3M sodium acetate,
Paisley, Scotland) supplemented with 5% FCS the samples were mixed with 2 vol of absolute
(Gibco: LPS levels <0.2 ng/ml), 2mM L-glum- ethanol and then placed at -70C overnight to
mine, 1mM pyruvate, penicillin 100 U/ml, strep- precipitate total RNA. Sedimentation at
tomycin 100 btg/ml (Flow Laboratories, Rockville, 13 200 x g for 30 min at 4C was performed and
MD) in a 5% CO2-humidified atmosphere at the resulting total RNA pellet was dried, resus-
37C. For experiments, the cells were collected, pended in diethyl pyrocarbonate (DEPC)-treated
washed and counted with a Coulter counter ZM, deionized water and its concentration was esti-
equipped with a Coultronic 256 channelizer mated by spectrophotometry. Total RNA (1-
(Coultronics, Margency, France). 21.tg) from monocytes and U937 cells was
reverse transcribed using random hexanucleo-
Determination ofcAMP and cGMP: For measur- tides as primers (First-strand cDNA synthesis kit,
ing the cytoplasmic cGMP and cAMP levels in Amersham France, Les Ulis, France). The cDNA
whole cells, monocytes were resuspended at generated was then amplified by the polymerase
7 x 106/ml. in RPMI 1640 medium supplemented chain reaction. After an initial denaturation step
with 2001M of the phosphodiesterase inhibitor at 94C, 30 PCR cycles were performed as
IBMX and incubated at 37C for 15 min. After follows: 25s at 95C, 1 min at 57C, 1 min at
the incubation period, 1 x 10 cells (135 I1) 72C, followed by a final extension step of 5 min
were distributed in duplicate or triplicate samples at 72C. The following oligonucleotide primers,
in Eppendorf microtubes. Fifteen !1 of the differ- based on the human endothelial cells cNOS
ent ligands were added for various periods of cDNA sequence, were used to amplify the mono-
incubation at 37C in a water bath. The reactions cytes and U937 NOS cDNA: forward, 5’-GCA TCA
were stopped by addition of 25 btl of 35% per- CCT ATG ACA CCC TCA GCG-3’; reverse, 5’-AGC
chloric acid (PCA)and immediate cooling on ice. TCG CTC TCC CTA AGC TGG TAG G-3’. These
The tubes were allowed to stand at 0C for 15 primers define a fragment of 277 bp. Oligonuc-
min, then spun at 3000 x g for 15 min. The leotides were synthesized by Genset (Paris,
pellets were discarded and the supernatants neu- France), except for control primers for human
tralized with KOH. The KC104 precipitates were [3-actin which were obtained from Stratagene (La
removed by a second centrifugation at 3 000 x g Jolla, CA, USA). Products of the reverse tran-
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scriptase-polymerase chain reaction (RT-PCR)
were analysed by agarose (1.4%) gel electrophor-
esis in the presence of BET.
Determination of [Ca2+]i: Cells were loaded
with 10 l.tM of the fluorescent probe Fluo 3-acet-
oxymethylester (Fluo 3-AM) for I h at 37C; the
cells were washed and resuspended in RPMI-
1640 medium, without phenol red, containing
10mM HEPES. Fluorescence intensity (in arbi-
trary units) of Fluo-3 AM-loaded U937 cells was
recorded as a function of the wavelength
between 500 and 600nm (maximum emission of
Fluo-3/Ca complex: 535nm), as described pre-
viously)
6 The free calcium concentration [Ca + ]i
in the cells is related to the fluorescence intensity
(F) by the following equation:
ca2 + ]i Kd X (F Fmin)/(Fmax F)
where Fmax is determined by measuring fluores-
cence after the cells are lysed in 0.1% Triton X-
100 (Sigma), whereas Fmin iS determined after
addition of 10mM EGTA. The effective constant
Kd of Fluo-3 in solution has been reported to be
400nM. Fluo-3 is analysed in the visible range,
thus the problems associated with the use of UV
light are avoided. In addition, the large increase
of the fluorescence emission by binding of Ca
2+
to Fluo-3 allows a great sensitivity for measuring
small variations in calcium concentration. How-
ever, upon binding of Ca
2 + there are no shifts in
its excitation or emission spectrum, which makes
Fluo-3 non-ratioable and therefore will compro-
mise the accuracy of absolute [Ca
2 + ]i determina-
tions. For these reasons, our data have been
presented as fluorescence intensities.
induced cAMP response was not significantly
affected, indicating that the increase in cAMP was
not secondary to a release of prostaglandins (not
shown).
IL-4 stimulates cyclic GMP accumulation in
human monocytes: The kinetics of IL-4 driven
cAMP and cGMP accumulation were compared in
unstimulated monocyte preparations from the
same donors and typical results are presented in
Fig. 3. It was regularly observed that the peak of
cGMP accumulation (between 3 and 10 min)
preceded that of late cAMP accumulation. For
eleven donors tested, the range of cGMP accu-
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FIG. 1. Kinetics of IL-4-induced cAMP accumulation in normal
human monocytes. Monocytes were incubated in triplicate
samples without or with IL-4 (10 ng/ml) for the times indicated,
and cAMP determination was performed as described in Materi-
als and Methods. Results are from one representative experi-
ment out of eleven, except for the detection of the first cAMP
transient which was observed only for three out of five donors
where this early time point was tested.
Results
IL-4 stimulates a biphasic cyclic AMP accumula-
tion in human monocytes: Incubation of freshly
isolated monocytes with IL-4 was found to result
in a delayed accumulation of cAMP, starting at
10- 15 min and peaking about 20- 25 min after
addition of the cytokine. For some donors, a
transient peak of cAMP was also observed after 1
min of stimulation, as shown in the typical
response presented in Fig. 1. After a phase of
plateau until 30 min, a progressive decrease
occurred and a return to the basal value was
achieved around 1 h after the beginning of the
stimulation (not shown). The increase in cAMP
content over background was usually in the
range 50- 300% (n 11). This late increase in
cAMP was dependent on the concentration of IL-
4, as presented in Fig. 2. When the experiments
were performed in the presence of 10 l.tM indo-
methacin, a cyclooxygenase inhibitor, the IL-4-
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FIG. 2. Dose-dependent induction of cAMP in monocytes by IL-4.
Human monocytes were stimulated for 20 min with medium
alone or with varying concentrations of IL-4 (0.1 100 ng/ml)
and cAMP accumulation was determined as previously describ-
ed. Results are the mean -I- S.D. of an experiment in triplicate
samples, representative of three.
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FIG. 3. Kinetics of IL-4-driven cGMP accumulation in human
monocytes. Monocytes were stimulated with IL-4 (10 ng/ml) for
the times indicated and cGMP concentrations were determined
by RIA on perchloric extracts, as described by Materials and
Methods. Data are mean -I- S.E.M. of triplicate samples from
one experiment representative of nine where a significant cGMP
response could be detected.
mulation, expressed as a percentage of the
control response in the presence of medium
alone, was 132- 396% (mean _+ S.D.
236 _+ 80; median 225). The induction of
cAMP and cGMP by IL-4 was specific, since it was
abrogated in the presence of 50 g/ml of a neu-
tralizing anti-IL-4 antibody, but not of an isotype-
matched irrelevant antibody as shown in Table 1.
Inbibitors of the nitric oxide syntbase pathway
impair the IL-4-driven cyclic nucleotides accu-
mulation in resting monocytes: The hetero-
dimeric soluble guanylyl cyclases, which convert
GTP into cGMP, are activated by NO-generating
compounds through interactions of the NO
radical with their haeminic prosthetic groups. In
order to test whether the observed accumulation
of cGMP in response to IL-4 was due to a gen-
eration of NO, two classical inhibitors of the I-
arginine pathway of NO synthase activation were
added to unstimulated monocytes prior to their
incubation with IL-4: t-NMMA, and nitro-t-argi-
nine which, at variance with L-NMMA, does not
compete with t-arginine for its transport into the
cells. As seen in Table 2, the IL-4-driven cGMP
accumulation was almost totally abolished in the
Table 1. IL-4-driven cyclic nucleotide accumulation in human
monocytes is inhibited with a specific neutralizing anti-lL-4
antibody
cAMP (fmol/106 cells) cGMP (fmol/106 cells)
Medium 460 -t- 50 410 -I- 110
IL-4 1500 -t- 190 1220 -t- 130
IL-4 + anti-lL-4 510 -I- 70 510 80
Monocytes were incubated for 3 min (cGMP) or 20 min (cAMP) with
medium, IL-4 (10ng/ml), or IL-4 and anti-lL-4 mAb (201g/ml). The
reactions were then stopped and cells extracts were determined for their
content in cAMP and cGMP as described in Materials and Methods.
Results are the mean -t- S.E.M. of triplicate samples from one
representative experiment out of two.
presence of these competitive inhibitors of t-argi-
nine for the NOS. Interestingly, IL-4-driven cAMP
accumulation was also markedly affected with t-
NMMA as shown in Fig. 4, suggesting that both
cAMP and cGMP production were related to the
NO pathway.
Effect of calcium chelator and calmodulin inbib-
itors on IL-4 driven cGMP accumulation:
Several NOS isoforms have been described,
which differ in their sensitivity to calcium for the
stimulation of their catalytic activity. Various inhi-
bitors of the Ca/CaM complex were thus tested
Table 2. Suppression of IL-4-driven cGMP accumulation by nitric
oxide synthase inhibitors
Expt Expt2 Expt3 Expt4 Expt5 Expt6
Medium 410 390 270 830 930 3500
IL-4 1900 900 730 2930 3730 5530
IL-4 + NT 340 300 800 700 3140
L-NMMA
Inhibition (%) 100 92 100 100 100
IL-4 + L-NA 900 350 285 NT 690 NT
Inhibition (%) 67 100 96 100
Monocytes from six different donors were incubated for various times
with medium, IL-4 (lOng/ml), or IL-4 and either mM of NG-mono
methyl-L-arginine (L-NMMA) or NG-nitro-L-arginine (L-NA). The reactions
were then stopped and cell extracts were determined for their content in
cGMP as described in Materials and Methods. Results are the mean of
triplicate samples and are expressed as fmoles cGMP/106 cells, at the
peak of the response (1 2 min).
1.0
0.0
IL-4 + L-NMMA IL-4 Medium
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FIG. 4. Effect of L-NMMA on IL-4-induced cAMP accumulation in
human monocytes. Monocytes were preincubated or not with L-
NMMA (1 mM) for 30 min at 37C, then stimulated for 20 min
with medium or IL-4 (10 ng/ml). Results are mean -t- S.E.M. of
triplicate samples from one representative experiment out of
seven. *p < 0.01" **p < 0.05.
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and, as seen in Table 3, the IL-4-stimulated cGMP
increase was greatly reduced either in the pre-
sence of the calcium chelator EGTA or of the
calmodulin inhibitor W7, both reagents being
ineffective alone at the concentrations tested.
Similar results were obtained with calmidazolium,
another inhibitor of the Ca/CaM complex (not
shown). These results therefore suggested that
the NOS involved may be different from the
inducible type II NOS detected in IFN-7-prein-
cubated monocytes and could be activated
through variations in intracytoplasmic calcium
concentration and therefore be related to the
constitutive NOS isoforms.
IL-4 stimulates an increase in intracytoplasmic
free calcium [Ca+ ]i in unstimulated monocytic
cells: Inasmuch as cNOS are regulated via tran-
sient calcium increases, we measured the effects
of IL-4 on the [Ca
2+ ]i in a monocytic cell line,
U937 cells, which behave like blood monocytes
with regard to cyclic nucleotide accumulation in
response to IL-4. As seen in Fig. 5, addition of
Table 3. Suppression of IL-4-driven cGMP accumulation in
human monocytes by calcium chelator and inhibitor of the Ca/
CaM complex
Expt Expt2 Expt3 Expt4 Expt5 Expt6
Medium 650 1000 670 530 1000 3500
IL-4 6160 2670 1160 1280 5670 5400
IL-4 + W7 670 1070 800 715 1690 2810
IL-4 + EGTA 630 930 710 NT 1340 NT
Monocytes from six different donors were stimulated for various times
with medium, IL-4 (100 ng/ml), IL-4 (100 ng/ml) and W-7 10 Ig/ml), or
IL-4 (lOOng/ml) + EGTA (2mM). Reactions were stopped and cell
extracts were analysed for cGMP content as described in Materials and
Methods. Results are mean of triplicate samples at the peak of the
response (1 -2 min) and are expressed as fmoles/108 cells. NT: not
tested.
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FIG. 5. IL-4 stimulates an increase in free calcium concentration
in U937 cells. Fluorescence intensity (in arbitrary units) of Fluo-3
AM-loaded U937 cells was recorded as a function of the wave-
length. U937 cells were successively exposed to medium, IL-4
(50 ng/ml), ionomycine (10 IM), and finally EGTA (10 mM).
Data are from one representative experiment out of three.
IL-4 to Fluo-3-1oaded resting U937 cells resulted
within 20s in a marked increase in [Ca2+].
Although Fluo-3 is not ratioable, an approximate
calculation gives a value of 78nM for the [Ca
2+ ]i
in the resting state which increased to about
1070nM after IL-4 administration. These results
were confirmed by micro-spectrofluorometric
techniques at the single cell level; high increases
in fluorescence intensity were recorded following
IL-4 addition to U937 cells, although we observed
that the response of individual cells was hetero-
geneous, some cells being unresponsive to IL-4
stimulation (data not shown). These results
demonstrate that IL-4 is able to elicit an increase
in [Ca
2+ ]i in monocytic cells, a prerequisite for
the activation of cNOS in these cells. Indeed, the
catalytic activity of the constitutive type I and III
cNOS are regulated by the Ca/CaM complex,
through an increase in the intracellular concentra-
tion of free calcium [Ca
2+ ]i evoked by specific
hormones or neurotransmitters. When calcium
ionophores such as ionomycine and A23187 were
added to monocytes, however, no increase in
cGMP over the basal concentration was detected,
nor any significant release of nitrite in the super-
natant of these cells; the same negative results
were obtained when monocytes or U937 cells
were incubated in the presence of thapsigargin,
an inhibitor of the endoplasmic reticulum
calcium ATPase, which constitutes another way to
raise the intracytoplasmic [Ca
2+ ]i. An increase in
[Ca2+], is therefore not sufficient, alone, to
trigger cGMP accumulation by monocytic cells.
Detection by RT-PCR of ype III eNOS mRNA in
human monoytic cells: Total RNA from human
monocytes and U937 cells were reverse tran-
scribed and amplified by the polymerase chain
reaction, using primers specific for the con-
stitutive endothelial human NO synthase. As seen
in Fig. 6, a fragment of 277 bp was readily
detected in U937 cells, which corresponds to the
size expected from the sequence of the endothe-
lial NO synthase. Although much weaker than that
of U937 cells, this band was also observed with
monocytes (not shown). Treatment of U937 cells
with either IL-4, or IL-4 and anti-C23 mAb, or
IFN-7, did not modify the expression of cNOS.
Discussion
We have previously observed that, for a fraction
of the donors tested, IL-4 induced a cGMP
increase in unstimulated monocytes; a much
higher response was detected when monocytes
were preincubated with IFN-7; this was inhibited
in the presence of L-NMMA and was not affected
by calcium chelation, suggesting the activation of
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FIG. 6. Detection by RT-PCR of a type III (endothelial) constitutive
cNOS mRNA in human monocytic cells. Total RNA (1- 2 Ig)
from monocytes and U937 cells was reverse transcribed and
amplified by PCR using specific primers for human ecNOS. RT-
PCR products were analysed by agarose (1.4%) gel electrophor-
esis in the presence of BET. Lane A: size markers (100 bp
ladder). Lane B: unstimulated U937 cells. Lane C: IL-4-activated
U937 cells. Lane D: IL-4 and anti-CD23 mAb-activated U937
cells. Lane E: IFN-7-activated U937 cells.
an iNOS. In addition, IL-4 induced a slight pro-
duction of nitrite by monocytes, which was
potentiated by IFN-y and inhibited by t-NMMA.
These results suggested that the sequential expo-
sure of monocytes to IFN-y and IL-4 elicited the
release of NO from t-arginine, which in turn was
able to stimulate soluble guanylate cyclase. We
have also reported that IL-4 induced an hetero-
geneous and late accumulation of nitrite in
monocyte supernatants.4 In the present work, we
show that IL-4 induces cAMP and cGMP genera-
tion in unstimulated human monocytes. A rather
large heterogeneity in the response of the differ-
ent individuals was observed, which may be
explained by the fact that, except for the absence
of HIV or hepatitis infection and of allergy, the
immunological status of these donors was largely
unknown. One cannot exclude the possibility that
some of these volunteers were primed otherwise
which may explain the variation in the response
observed and the biphasic cAMP response which
was detected for some of them. We have no
direct explanation for this early cAMP increase;
tentatively, one may speculate that it could be
achieved through a cross stimulation of 2 recep-
tors, inasmuch as we have previously demon-
strated a functional interplay between the
response of monocytes to IL-4 and to 2 agonists.
Hart et al. did not detect significant cAMP accu-
mulation in elutriation-enriched monocytes stimu-
lated by IL-4 or IL-4 plus LPS; however, their
experiments were performed with low concentra-
tion of It-4 (1 ng/ml), that, in our hands too, only
triggered a slight cAMP increase, whereas higher
IL-4 concentrations stimulated significant increa-
ses in both cyclic nucleotides.
The IL-4 receptor binding unit and its y chain-
associated component do not belong to the
family of receptors with seven spanning domains,
capable of interacting with Gst and leading to
the activation of adenylate cyclase (AC). Further.
more, whether the associated y chain has been
detected in lymphoid cells, it appears to be
absent in monocytic cells, as revealed by RT-
PCR.38’39 The late accumulation of c_AMP sug-
gested therefore an indirect mechanism of action
of IL-4. Activation of AC via the induction of
prostaglandin by IL-4 was ruled out, since the It-
4-driven cAMP accumulation was not significantly
affected in the presence of indomethacin, an
inhibitor of cyclooxygenase. Alternatively,-the
observed IL-4-induced cAMP accumulation could
result from AC stimulation through the activation
of PKC or of the calcium/calmodulin complex.
4
The role of protein kinase C (PKC) and cyclic
nucleotides in IL-4 signalling is controversial.
Arruda and HO4 presented evidence that, in
human monocytes, IL-4 signalling involved PKC
translocation to a nuclear fraction, without paral-
lel increase in [Ca
2+ ]i, suggesting a possible role
for phosphatidylcholine hydrolysis in this process;
the same group has shown recently that IL-4 sig-
nalling in monocytes and U937 cells involves the
activation of a phosphatidylcholine-specific phos-
pholipase C (PC-PLC), but not of phosphatidyli-
nositol 4,5-bisphosphate phospholipase C (PIP2-
PEg), PEA2, PLD nor sphingomyelinase.
42 In con-
trast, our data clearly indicate that 1L-4 stimulates
an increase in [Ca
2+ ]i in human promonocytic
U937 cells, despite the usual considerable varia-
tion which was observed when the response of
individual cells was measured. The fluorescent
probe we used, Fluo-3 is slightly more convenient
for detecting small variations in calcium con-
centration than Fura-2, used by Ho et al., but this
is not sufficient to explain the reasons for this
discrepancy. Alternatively there may exist differ-
ences between various sub-clones of U937 cells.
Our kinetic studies indicate that the late peak of
c_AMP generation is preceded by an increase in
cGMP. At variance with the results observed with
rodent monocytes, where a 30- 100 fold differ-
ence between cAMP and cGMP levels has been
reported,4 our data indicate that the basal con-
centration of cGMP is roughly of the same order
of magnitude as that of cGMP, which is more in
agreement with the results obtained for human
monocytes by Li et a/.44 The differential kinetics
of the cGMP and cAMP increases suggested a
possible link between the accumulation of these
two cyclic nucleotides. Indeed, both cGMP and
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cAMP accumulation were suppressed by I-NMMA
and nitro-t-arginine, two inhibitors of the NO syn-
thase (NOS). Nitric oxide (NO), which has been
identified in recent years as a pleiotropic media-
tor,45-48 is a short-lived radical generated by oxi-
dation of the guanidino group of I-arginine by
constitutive or inducible NO synthases.49-52
Soluble guanylate cyclase is activated by NO
through interaction with its haeminic group,
which leads to increased cGMP concentration.
The subsequent cAMP increase we observed
following addition of IL-4 to monocytes could
then result from an interplay in the cyclic nucleo-
tide phosphodiesterases (CN-PDE) network.
Noteworthy, Li et al.44 have reported that IL-4 and
IFN-3, synergistically elicited a marked increase in
cAMP phosphodiesterase activity in human mono-
cytes. We have also observed that IL-4 stimulated
CN-PDE activity in resting monocytes (not
shown). This high CN-PDE activity may help
explain the decrease in cAMP and cGMP levels
observed in time, despite the presence of IBMX, a
nonspecific inhibitor of the various CN-PDE iso-
zymes. Whereas Endres et al. observed that CN-
PDE inhibitors such as IBMX suppressed the LPS-
induced TNF-0t production by human mono-
nuclear cells (PBMC) through the accumulation
of cAMP,5 Paul-Eugene et al. recently reported
that low concentrations of IBMX (10 gtM) poten-
tiated the IL-4-driven IgE production and sCD23
release by PBMC.54
The cGMP increase might activate the cGMP-
inhibitable cAMP-specific phosphodiesterase,
(type III CN-PDE), that would result in sub-
sequent cAMP accumulation, independent of the
activation of adenylyl cyclase and might explain
the delayed phase of cAMP increase. Experiments
are in progress to study this mechanism and pre-
liminary results suggest that both chemical NO
donators and permeant cGMP analogues, such as
Sp-cGMPS, are able to trigger cAMP accumulation
in monocytic cells.
Both cGMP and cAMP increases were affected
in the presence of EGTA, a calcium chelator, and
of W-7 or calmidazolium, two inhibitors of the
calcium/calmodulin complex. In contrast with
the calcium/calmodulin-dependent activation of
constitutive NOS, the activation of inducible
forms of NOS (iNOS) is regulated by transcrip-
tion; once translated, the protein tightly associ-
ates with calmodulin, explaining the relative
insensitivity of iNOS to modifications of the intra-
48 cellular calcium concentration. However, the
iNOS from human hepatocytes, or Hep-NOS, is
partially inhibited by calcium chelators and by
antagonists of calmodulin; furthermore, natural
and recombinant Hep-NOS might differ in their
sensitivity to calcium and calmodulin.52
The NO synthase activated by IL-4 in unstimu-
lated monocytes may therefore be of the con-
stitutive type, inasmuch as an endothelial type
cNOS mRNA can be detected in these cells by
RT-PCR. The presence of both inducible iNOS
(type II) and constitutive endothelial NOS (type
III) mRNA has been recently reported in human
monocytes and monocytic cell lines, such as
U937;
55 interestingly, stimulation with IFN-, and
TNF-cz led to an induction of iNOS mRNA
expression, whereas cNOS mRNA was reduced in
the same time. A reciprocal regulation of cNOS
and iNOS mRNA has already been observed in
other cell types, suggesting the control of their
expression by coordinated mechanisms. In our
investigation, however, we did not detect a sig-
nifican reduction of cNOS mRNA following the
addition of IFN-2 alone. In addition, treatment
with either IL-4, or IL-4 and anti-C23, did not
modify the expression of cNOS mRNA in U937
cells. In contrast, these treatments were found to
induce the expression of the inducible iNOS,
both at the mRNA level, as detected by RT-PCR,
and at the protein level, as revealed by immuno-
chemistry (Dugas et al.; manuscript in prepara-
tion and Reference 56).
Preliminary immunofluorescence experiments,
using a mouse monoclonal antibody against anti-
human endothelial NOS (Affinity Research Pro-
ducts, Nottingham, UK) confirm the existence of
an endothelial type cNOS protein in monocytic
cells such as U937. Experiments are in progress to
determine if this protein is enzymatically active
and whether it is also present in human blood
monocytes. Our results also indicate that a
calcium increase, by itself, is not sufficient to
trigger the activation of cNOS in monocytic cells.
They suggest that IL-4 provides other signals or
co-factors that are required to obtain a full cataly-
tic activity. One such co-signal could be related to
tyrosine phosphorylation, inasmuch as the cataly-
tic activity of another type of constitutive NOS, the
neuronal enzyme, is impaired in the presence of
tyrosine kinase inhibitors.57 Indeed, preliminary
data suggest that IL-4-induced cGMP accumulation
may be impaired by tyrosine kinase inhibitors.
These results indicate that different isoforms of
NO synthase, constitutive and inducible, may be
expressed in human monocytes, depending on
their stage of differentiation and the combination
of signals provided.
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